- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Can Global Policies to Boost Biosimilar Adoption Work in the US?
On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
On this episode of Not So Different, The Center for Biosimilars® celebrating Global Biosimilars Week—an annual advocacy campaign promoting the use of biosimilars worldwide orchestrated by the International Generics and Biosimilars Association.
Joining us for this special episode is Craig Burton, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines. Craig is a leading voice in the biosimilar space, and together, we’ll explore a fascinating and timely question: Can global policies to boost biosimilar adoption work in the US?
From government incentives and substitution policies to international trade agreements and health equity strategies, we’ll dive into lessons learned from around the world. How do Europe, Canada, Latin America, Australia, and others foster biosimilar growth—and what can the US learn from these approaches?
Show notes
To learn more about GBW, click here.
To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here.
To learn more about product hopping, click here.
To read part 1 of our GBW series, click here.
To read part 2 of our GBW series, click here.
To read part 3 of our GBW series, click here.
To hear another episode featuring more of Craig's thoughts on the Biden's administration's impact on the biosimilar industry, click here.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
